Oncoteq

Clinical-stage biotech leveraging AI for oncology drug development.

Website: https://www.oncoteq.ch/

Cover Block

PUBLIC

Field Value
Name Oncoteq AG
Tagline Clinical-stage biotech leveraging AI for oncology drug development
Headquarters Cham, Switzerland
Founded 2022
Stage Seed
Business Model B2B
Industry Healthtech / Oncology
Technology Type Biotech / Life Sciences (AI-supported drug development)
Geography Western Europe
Growth Profile Venture Scale
Funding Label Seed (lead: Cureteq)

Links

PUBLIC

Executive Summary

PUBLIC

Oncoteq AG is a Cham-based clinical-stage oncology biotech assembled inside the Cureteq company-builder platform, with a thesis that AI-supported asset selection plus disciplined in-licensing can compress the cost and timeline of early oncology development [Oncoteq] [Cureteq]. The company was founded and seeded by Cureteq, a Partex group entity, and operates as one of several therapeutic-area vehicles in that portfolio [Cureteq]. Its current pipeline comprises three named assets, TEQ101, TEQ102 and TEQ103, with the latter two acquired through in-licensing transactions disclosed in late 2023 [Oncoteq, Nov 2023]. TEQ102, formerly TUB-010, is an anti-CD30 antibody-drug conjugate in-licensed from Tubulis GmbH for T-cell and Hodgkin's lymphoma indications [ADC Review] [IZB]. TEQ103 is a worldwide-exclusive license targeting estrogen receptor alpha positive breast cancer through a stress-response mechanism [Oncoteq, Nov 2023] [IGB Illinois]. Leadership is anchored by CEO Mads Dalsgaard, CBO Sarah Holland, and CFO Swati Mehta, with the CFO role disclosed via Cureteq's J.P. Morgan Healthcare Conference 2024 communications [Cureteq, Jan 2024]. The next 12 to 18 months should clarify whether Oncoteq can convert in-licensed assets into IND-enabling progress, and whether the Cureteq builder model can attract crossover capital beyond its parent.

Data Accuracy: GREEN -- Confirmed across the Oncoteq corporate site, Cureteq portfolio page, and Swiss Moneyhouse registry.

Taxonomy Snapshot

Axis Value
Stage Seed, clinical-stage assets
Business Model B2B (drug developer; out-licensing / partnering optionality)
Industry / Vertical Oncology therapeutics
Technology Type Antibody-drug conjugates and small molecules, AI-supported asset selection
Geography Switzerland (Cham, Canton of Zug)
Growth Profile Venture scale, capital-intensive
Funding Seed, undisclosed amount, lead Cureteq

Company Overview

PUBLIC

Oncoteq is a clinical-stage oncology biotech founded in 2022 and headquartered at Maschinengasse 10, 6330 Cham, in the Swiss Canton of Zug, registered as Oncoteq AG under Swiss commercial identifier CHE-234.928.941 [Oncoteq] [Moneyhouse]. The company describes itself as a vehicle that "leverages AI to unlock the value of exciting oncology assets," wording that is taken directly from its corporate site and which sits inside the broader Cureteq platform thesis of combining a flexible biotech company-builder with AI-supported drug development [Oncoteq] [Cureteq]. Cureteq, in turn, is part of the Partex group, and Oncoteq is listed alongside other therapeutic-area entities on the Cureteq portfolio page as the entity "responsible for the development of TEQ101, TEQ102 and TEQ103" [Cureteq].

The public milestone trail is short but coherent. Following formation in 2022, Oncoteq announced two in-licensing transactions in November 2023: an agreement with Munich-based Tubulis GmbH bringing in TUB-010 (renamed TEQ102), an IND-ready anti-CD30 antibody-drug conjugate, and a separate worldwide-exclusive license for TEQ103, a breast cancer compound originating from academic work associated with the Institute for Genomic Biology in Illinois [Oncoteq, Nov 2023] [IZB] [IGB Illinois]. In August 2024 the company sponsored Tiffany's Pink Pedal Ride for breast cancer research, a small but consistent signal that breast cancer is being positioned as part of the public narrative around TEQ103 [Oncoteq]. No subsequent priced financing round, partnership, or clinical-trial initiation has been publicly disclosed at the time of writing.

Legal and operating structure is straightforward: a Swiss AG capitalized initially by Cureteq, with leadership and corporate development run from Cham. The company-builder model means that shared services, scientific advisory, and capital allocation decisions sit at least partly at the Cureteq layer, which is relevant context for any investor evaluating Oncoteq as a standalone investment opportunity rather than a portfolio line item.

Data Accuracy: GREEN -- Corroborated by the Oncoteq corporate site, Cureteq portfolio page, and the Moneyhouse Swiss registry entry.

Product and Technology

MIXED

Oncoteq's product surface is its pipeline, and the pipeline currently presents three assets [PUBLIC]. TEQ101 is named on the corporate pipeline page but its mechanism and indication are not disclosed in any public source captured during research, so investors should treat it as an early-stage placeholder pending further disclosure [Oncoteq]. TEQ102 is the most clinically advanced asset described publicly: an anti-CD30 antibody-drug conjugate in-licensed from Tubulis GmbH, formerly designated TUB-010, positioned for the treatment of T-cell lymphoma and Hodgkin's lymphoma [Oncoteq, Nov 2023] [ADC Review] [IZB]. The asset was reported as IND-ready at the time of out-licensing from Tubulis, which materially shortens the time-to-clinic compared with a discovery-stage molecule [IZB].

TEQ103 is a small-molecule compound with a differentiated mechanism: it targets estrogen receptor alpha (ERα) positive breast cancer cells and selectively kills cells with an activated unfolded protein response (a-UPR), a stress-response axis that is mechanistically distinct from the SERD and CDK4/6 inhibitor classes that dominate current ER+ standard-of-care [Oncoteq, Nov 2023] [IGB Illinois]. Oncoteq holds a worldwide exclusive license for TEQ103 [Oncoteq, Nov 2023]. The combined pipeline therefore spans two modalities (ADC and small molecule) and two tumor-type clusters (hematologic malignancy and ER+ breast cancer), which is unusually broad for a seed-stage biotech and reflects the in-licensing posture of the parent Cureteq platform [PUBLIC].

The AI element of Oncoteq's positioning is described at the platform level rather than disclosed as a proprietary computational stack [MIXED]. The Cureteq platform language refers to "AI supported drug development" combined with a "company-builder model" [Cureteq]. Public sources do not detail which models, datasets, or workflows are used, whether the AI capability is built in-house at Cureteq or sourced from Partex group assets, or how AI was specifically applied in the selection of TEQ102 and TEQ103. Investors should treat the AI claim as a sourcing-and-triage advantage at the platform level until the company publishes more specific evidence [PRIVATE inference].

Data Accuracy: YELLOW -- Pipeline assets and mechanisms are corroborated across Oncoteq, Tubulis-related, and IGB Illinois sources; the AI methodology is described only in marketing language and remains single-source.

Market Research and Opportunity

PUBLIC

Oncology drug development remains the largest therapeutic spending category in pharmaceuticals, and the two indication clusters Oncoteq has chosen sit inside well-characterized commercial markets. The company's own framing for TEQ103 references a global breast cancer treatment market of approximately USD 25 to 30 billion annually [Oncoteq, Nov 2023]. ER+/HER2- disease accounts for roughly two-thirds of breast cancer cases in most published epidemiology, which makes it the single largest commercial sub-segment within that figure (analogous market context). For TEQ102, the addressable patient populations are smaller in absolute count: classical Hodgkin lymphoma and CD30-expressing T-cell lymphomas are niche but have established ADC precedent through brentuximab vedotin (Adcetris), which has demonstrated that anti-CD30 ADCs can support multi-billion-dollar franchises (analogous market context).

Sizing claim Value Source
Global breast cancer treatments, annual ~USD 25-30 billion [Oncoteq, Nov 2023]

Analyst takeaway: the only company-cited sizing figure is the breast cancer market envelope, which establishes the order of magnitude of the TEQ103 prize but does not, on its own, constitute a TAM/SAM build for Oncoteq specifically. ER+ breast cancer is a segment where the standard of care is being actively reshaped by oral SERDs and antibody-drug conjugates, and a mechanism that targets stress-response biology in ERα+ cells is genuinely differentiated if it can demonstrate selectivity in vivo.

Demand drivers for the company's chosen indications are durable. Hodgkin lymphoma and T-cell lymphoma patients who relapse after frontline therapy remain an area of unmet need, and the commercial precedent set by Adcetris means payers and prescribers are familiar with the CD30-ADC value proposition. In ER+ breast cancer, recurrence and endocrine-resistance after initial therapy continue to drive demand for novel mechanisms; the recent approvals of elacestrant and the late-stage progress of multiple oral SERDs demonstrate that buyers and regulators are receptive to mechanism diversification in this segment (analogous market context).

Regulatory and macro forces cut both ways. EMA and FDA both maintain accelerated pathways for oncology assets that show meaningful activity in defined molecular sub-populations, which favors targeted mechanisms like TEQ103. Conversely, the cost of running registration-enabling oncology trials has risen materially over the past five years, and a seed-stage Swiss biotech reliant on a single disclosed investor will need either a meaningful Series A, a development partner, or both, to push any of its three assets through the next inflection point.

Data Accuracy: YELLOW -- The single sizing figure is company-sourced and directional; surrounding market context is drawn from established public knowledge of the indications rather than a named third-party report captured in research.

Competitive Landscape

MIXED

Oncoteq competes on two distinct fronts that share almost no overlap: the anti-CD30 ADC space for hematologic malignancy via TEQ102, and ER+ breast cancer via TEQ103. No direct competitors were named in the structured facts, so the analysis below is built from indication-level public knowledge of incumbents and challengers.

In the CD30-ADC segment, the unambiguous incumbent is brentuximab vedotin (Adcetris), commercialized by Pfizer (post-Seagen acquisition) and Takeda outside the United States. Adcetris has reshaped frontline and relapsed Hodgkin lymphoma treatment and remains the benchmark any new CD30-targeted ADC will be measured against on efficacy, payload chemistry, and tolerability. The differentiated angle for TEQ102 is the Tubulis P5 conjugation chemistry that originated the asset, which Tubulis has publicly positioned as designed to improve the therapeutic index of ADCs through more stable linker-payload pairing [IZB]. Whether that translates into a meaningful clinical advantage is the central scientific question for TEQ102, and it will only be answered in the clinic. Adjacent challengers in the broader ADC space include companies advancing next-generation conjugation platforms; Oncoteq does not own the underlying chemistry but holds the development and commercialization rights to this specific molecule.

In ER+ breast cancer, the competitive set is denser and better capitalized. Standard of care is dominated by CDK4/6 inhibitors (Pfizer's Ibrance, Novartis's Kisqali, Lilly's Verzenio) layered on endocrine therapy, with Stemline/Menarini's elacestrant now established as the first oral SERD and a deep bench of follow-on oral SERDs in late-stage development at AstraZeneca, Roche, and Lilly. Antibody-drug conjugates including Enhertu and Trodelvy are also expanding into ER+ disease. Against that backdrop, TEQ103's a-UPR-targeting mechanism is genuinely distinct, but it enters a market where prescribers have many shots on goal and where any new entrant must demonstrate either superior activity in endocrine-resistant disease or a tolerability advantage that supports earlier-line use [Oncoteq, Nov 2023] [IGB Illinois].

Where Oncoteq has a defensible edge today, it is in capital efficiency rather than scientific moat: the Cureteq company-builder model lets it stand up a clinical-stage entity around in-licensed assets without the overhead of a discovery organization, and the worldwide exclusive license on TEQ103 plus the IND-ready status of TEQ102 means there is real optionality on the next eighteen months [Cureteq] [Oncoteq, Nov 2023] [IZB]. Where it is most exposed is in financing depth and clinical execution capacity: the named comparators in both indications are funded at multiples of Oncoteq's disclosed capitalization, and the company will need either a strategic partner, a meaningful priced round, or strong early clinical signals to remain competitive past initial dose-finding work. The plausible 18-month scenario: a winner-if-X case is positive Phase I dose-escalation data on TEQ102 attracting an ADC-focused partner and validating the platform; a loser-if-Y case is delayed IND filings combined with no follow-on financing, which would force Oncoteq to narrow to a single asset.

Data Accuracy: YELLOW -- Subject-company facts are GREEN; competitor framing draws on established public knowledge of named oncology incumbents rather than a captured comparison report.

Opportunity

PUBLIC

The size of the prize for Oncoteq is bounded less by market access and more by clinical execution: if either TEQ102 or TEQ103 generates convincing early human data, the asset values are independently meaningful, and the company sits inside a builder platform designed to compound that into a portfolio.

The headline opportunity. The most credible large outcome for Oncoteq is to become a focused clinical-development house that converts two in-licensed assets into partnered or out-licensed programs at IND or Phase Ib inflection points, with TEQ103 as the lead value driver in a roughly USD 25 to 30 billion global breast cancer treatment market [Oncoteq, Nov 2023]. The cited evidence makes that outcome reachable rather than aspirational because TEQ102 was reported as IND-ready at the point of in-licensing from Tubulis, compressing the typical seed-to-clinic timeline by years [IZB], and because TEQ103's mechanism is differentiated from the dominant SERD and CDK4/6 classes in ER+ breast cancer [IGB Illinois]. A focused biotech with one approved or partnered oncology asset can support a valuation in the mid-hundreds of millions to low billions of dollars; that is the realistic ceiling Oncoteq is playing for if execution holds.

Growth scenarios.

Scenario What happens Catalyst Why it's plausible
Partnered ADC TEQ102 reaches clinic and attracts a strategic partner for hematologic-malignancy development Positive Phase I dose-escalation in CD30+ lymphoma Adcetris precedent and Tubulis P5 chemistry pedigree validate the modality [IZB]
ER+ breakout TEQ103 generates clean monotherapy signal in endocrine-resistant ER+ breast cancer First-in-human readout demonstrating a-UPR-mediated tumor regression Mechanism is orthogonal to the dominant SERD/CDK4/6 axis [IGB Illinois] [Oncoteq, Nov 2023]
Platform compounding Cureteq adds further in-licensed assets into Oncoteq, increasing pipeline shots on goal Additional in-licensing announcements through Cureteq channels Builder model is explicitly designed for serial asset acquisition [Cureteq]

What compounding looks like. The flywheel here is platform-level rather than product-level. Each successfully in-licensed and de-risked asset increases Cureteq's credibility as a counterparty for academic and biotech licensors, which in turn improves access to the next generation of assets at favorable economics. The two 2023 in-licensing transactions, completed within weeks of each other, are early evidence that the sourcing engine is functional [Oncoteq, Nov 2023] [IZB]. AI-supported triage, if it delivers the asset-selection edge the company describes, would compound that advantage further by lowering the false-positive rate on in-licensed candidates [Cureteq].

The size of the win. Comparable transactions in oncology asset development provide a useful frame. ImmunoGen, an ADC-focused developer, was acquired by AbbVie in 2023 for approximately USD 10.1 billion on the strength of a single approved ADC franchise, and Seagen was acquired by Pfizer for USD 43 billion in the same year, anchored by the Adcetris and Padcev franchises (analogous transaction context). Oncoteq is many clinical milestones away from those outcomes, and any reference to those numbers is a scenario, not a forecast. A more proximate scenario: an out-licensing or co-development deal on a single de-risked asset at the Phase Ib inflection point in oncology has historically commanded upfront payments in the tens to low-hundreds of millions of dollars range with development milestones into the high hundreds of millions (analogous deal context). That is the order-of-magnitude prize the next 18 to 24 months are playing for.

Data Accuracy: YELLOW -- Pipeline and licensing facts are GREEN-cited; comparable transaction values are widely reported public knowledge but were not captured as primary sources in this research pass and are explicitly labelled scenario context.

Sources

PUBLIC

  1. [Oncoteq] Oncoteq corporate site | https://www.oncoteq.ch/

  2. [Oncoteq] About Us, Oncoteq | https://www.oncoteq.ch/about-us/

  3. [Oncoteq] Pipeline, Oncoteq | https://www.oncoteq.ch/pipeline/

  4. [Oncoteq] Platform, Oncoteq | https://www.oncoteq.ch/platform/

  5. [Oncoteq] Investors and Media, Oncoteq | https://www.oncoteq.ch/investors-media/

  6. [Oncoteq] Team, Oncoteq | https://www.oncoteq.ch/about-us/team/

  7. [Oncoteq] Contact, Oncoteq | https://www.oncoteq.ch/contact/

  8. [Oncoteq, Nov 2023] Oncoteq expands pipeline with TEQ103, a promising treatment for breast cancer | https://www.oncoteq.ch/2023/11/oncoteq-expands-pipeline-with-teq103-a-promising-treatment-for-breast-cancer/

  9. [Oncoteq, Nov 2023] Press release: Oncoteq completes another in-licensing deal, adding a potential best-in-class CD30 ADC from Tubulis | https://www.oncoteq.ch/2023/11/oncoteq-completes-another-in-licensing-deal-adding-a-potential-best-in-class-cd30-antibody-drug-conjugate-from-tubulis-to-its-oncology-pipeline/

  10. [Cureteq] Oncoteq portfolio page, Cureteq | https://www.cureteq.com/portfolio/oncoteq/

  11. [Cureteq] Portfolio, Cureteq | https://www.cureteq.com/portfolio/

  12. [Cureteq, Jan 2024] Meeting at J.P. Morgan 2024, Cureteq | https://www.cureteq.com/2024/01/meeting-at-j-p-morgan-2024/

  13. [IZB] Tubulis out-licenses IND-ready ADC for the treatment of lymphoma to Oncoteq | https://www.izb-online.de/en/izb-biotech-news/tubulis-out-licenses-ind-ready-adc-for-the-treatment-of-lymphoma-to-oncoteq-innovations-und-gruenderzentrum-biotechnologie-izb/

  14. [Crunchbase] Cureteq AG, Crunchbase profile | https://www.crunchbase.com/organization/cureteq-ag

  15. [Moneyhouse] Oncoteq AG in Cham, Moneyhouse company report | https://www.moneyhouse.ch/en/company/oncoteq-ag-20514838621

  16. [LinkedIn] Cureteq AG, a Partex Company, LinkedIn page | https://ch.linkedin.com/company/cureteq

Articles about Oncoteq

View on Startuply.vc